HUTCHMED (00013.HK) Vests 0.73 Million LTIP Shares to CEO and CFO

Bulletin Express03-11

HUTCHMED (China) Limited disclosed that 726,317 ordinary shares granted under its Long Term Incentive Plan (LTIP) on 5 June 2023 vested on 10 March 2026, following the company’s 2025 results announcement on 5 March 2026.

Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su received 524,079 shares, equivalent to 0.52 million shares, while Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng received 202,238 shares, or 0.20 million shares. The awards vested at no cost to the executives and were conducted outside a trading venue, in line with the UK Market Abuse Regulation notification requirements.

The vesting forms part of HUTCHMED’s ongoing LTIP aimed at aligning senior management incentives with long-term shareholder interests. The company, dual-listed on Nasdaq, AIM and the Hong Kong Stock Exchange, focuses on developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases.

No other terms or financial considerations were disclosed in the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182771475?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182771475","market":"hk","top_or_hot":-1,"title":"HUTCHMED (00013.HK) Vests 0.73 Million LTIP Shares to CEO and CFO","media":"Bulletin Express","content":"<p>HUTCHMED (China) Limited disclosed that 726,317 ordinary shares granted under its Long Term Incentive Plan (LTIP) on 5 June 2023 vested on 10 March 2026, following the company’s 2025 results announcement on 5 March 2026.</p>\n<p>Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su received 524,079 shares, equivalent to 0.52 million shares, while Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng received 202,238 shares, or 0.20 million shares. The awards vested at no cost to the executives and were conducted outside a trading venue, in line with the UK Market Abuse Regulation notification requirements.</p>\n<p>The vesting forms part of HUTCHMED’s ongoing LTIP aimed at aligning senior management incentives with long-term shareholder interests. The company, dual-listed on Nasdaq, AIM and the Hong Kong Stock Exchange, focuses on developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases.</p>\n<p>No other terms or financial considerations were disclosed in the filing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013.HK) Vests 0.73 Million LTIP Shares to CEO and CFO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013.HK) Vests 0.73 Million LTIP Shares to CEO and CFO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-11 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (China) Limited disclosed that 726,317 ordinary shares granted under its Long Term Incentive Plan (LTIP) on 5 June 2023 vested on 10 March 2026, following the company’s 2025 results announcement on 5 March 2026.</p>\n<p>Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su received 524,079 shares, equivalent to 0.52 million shares, while Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng received 202,238 shares, or 0.20 million shares. The awards vested at no cost to the executives and were conducted outside a trading venue, in line with the UK Market Abuse Regulation notification requirements.</p>\n<p>The vesting forms part of HUTCHMED’s ongoing LTIP aimed at aligning senior management incentives with long-term shareholder interests. The company, dual-listed on Nasdaq, AIM and the Hong Kong Stock Exchange, focuses on developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases.</p>\n<p>No other terms or financial considerations were disclosed in the filing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"","article_id":"1182771475","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182771475","pubTimestamp":1773218577,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HUTCHMED (China) Limited disclosed that 726,317 ordinary shares granted under its Long Term Incentive Plan (LTIP) on 5 June 2023 vested on 10 March 2026, following the company’s 2025 results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药"},"translate_title":"和黄医药(00013.HK)向首席执行官和首席财务官授予73万股LTIP股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"HUTCHMED (China) Limited disclosed that 726,317 ordinary shares granted under its Long Term Incentive Plan (LTIP) on 5 June 2023 vested on 10 March 2026, following the company’s 2025 results announcement on 5 March 2026.\nChief Executive Officer and Chief Scientific Officer Dr Weiguo Su received 524,079 shares, equivalent to 0.52 million shares, while Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng received 202,238 shares, or 0.20 million shares. The awards vested at no cost to the executives and were conducted outside a trading venue, in line with the UK Market Abuse Regulation notification requirements.\nThe vesting forms part of HUTCHMED’s ongoing LTIP aimed at aligning senior management incentives with long-term shareholder interests. The company, dual-listed on Nasdaq, AIM and the Hong Kong Stock Exchange, focuses on developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases.\nNo other terms or financial considerations were disclosed in the filing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182771475","isCrawlerRequest":true}